37 results on '"Katalinic, Alexander"'
Search Results
2. Incidence, mortality and trends of cutaneous squamous cell carcinoma in Germany, the Netherlands, and Scotland.
- Author
-
Keim, Ulrike, Katalinic, Alexander, Holleczek, Bernd, Wakkee, Marlies, Garbe, Claus, and Leiter, Ulrike
- Subjects
- *
REPORTING of diseases , *MATHEMATICAL models , *MORTALITY , *DISEASE incidence , *SKIN tumors , *THEORY , *SQUAMOUS cell carcinoma - Abstract
Cutaneous squamous cell carcinoma (cSCC) incidences are increasing but scarcely available separated. We analysed incidence rates of cSCC over three decades with an extrapolation to 2040. Cancer registries from the Netherlands, Scotland and two federal states of Germany (Saarland/Schleswig-Holstein) were sourced for separate cSCC incidence data. Incidence and mortality trends between 1989/90 and 2020 were assessed using Joinpoint regression models. Modified age-period-cohort models were applied to predict incidence rates up to 2044. Rates were age-standardised using the new European standard population (2013). Age-standardised incidence rates (ASIR, per 100,000 persons per year) increased in all populations. The annual percent increase ranged between 2.4% and 5.7%. The highest increase occurred in the age groups ≥60 years, especially in men aged ≥80 years, with a three to 5-fold increase. Extrapolations up to 2044 showed an unrestrained increase in incidence rates in all countries investigated. Age-standardised mortality rates (ASMR) showed slight increases between 1.4 and 3.2% per year in Saarland and Schleswig-Holstein for both sexes and for men in Scotland. For the Netherlands, ASMRs remained stable for women but declined for men. There was a continuous increase of cSCC incidence over three decades with no tendency for levelling-off, especially in the older populations as males ≥80 years. Extrapolations point to a further increasing number of cSCC up to 2044, especially among ≥60 years. This will have a significant impact on the current and future burden on dermatologic health care which will be faced with major challenges. • Age standardised incidence rates separated of cutaneous squamous cell carcinoma from four European registries were analysed. • An annual increase between +2.4% and +5.7% was observed over three decades. • Highest increases occurred in ages ≥60, especially in men ≥80. • Age-standardised mortality rates are rising in Germany and Scotland. • In extrapolations until 2044, an increase up to 5-fold in ages ≥60 is expected. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
3. Nachbefragung zur Qualitätssicherung der ELISA-Kohortenstudie zur COVID-19-Prävalenz: Die Sicht von Studienteilnehmerinnen und Studienteilnehmern – Was kommt gut an?
- Author
-
Peters, Elke, Alabid, Aiham, Elsner, Susanne, Klein, Christine, Borsche, Max, Rupp, Jan, and Katalinic, Alexander
- Published
- 2022
- Full Text
- View/download PDF
4. A critical appraisal of safety data on dydrogesterone for the support of early pregnancy: a scoping review and meta-analysis.
- Author
-
Katalinic, Alexander, Shulman, Lee P., Strauss, Jerome F., Garcia-Velasco, Juan A, and van den Anker, John N.
- Subjects
- *
FETAL abnormalities , *FIXED effects model , *RECURRENT miscarriage , *REPRODUCTIVE technology , *PREGNANCY - Abstract
No data support the suggestion that first-trimester dydrogesterone use increases the risk of fetal abnormalities; however, two low-quality retrospective studies (one retracted by the journal) have suggested such a link. A scoping review and meta-analysis were carried out to address this discrepancy. The literature was reviewed but it was not possible to identify any evidence of a plausible mechanism for potential causality between dydrogesterone and fetal abnormalities. To investigate whether any evidence existed, a preliminary meta-analysis was undertaken of clinical studies published since 2005 on first-trimester dydrogesterone use with assessment of fetal abnormalities. A fixed effects model was used to determine pooled odds ratios with 95% confidence intervals (95% CI). From 83 articles identified, six randomized controlled trials were included. Pooled risk ratios (RR) for maternal dydrogesterone use and fetal abnormalities gave a RR approaching 1 (RR 0.96; 95% CI 0.57, 1.62), confirming previous conclusions of no causal association between fetal abnormalities and first-trimester dydrogesterone use. Physicians, scientists and journal reviewers should exercise due diligence to prevent promulgation of retracted data. We are confident in using dydrogesterone, if indicated, in the treatment of threatened or recurrent miscarriage, and believe that its favourable safety profile should extend to its appropriate use in assisted reproductive technologies. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
5. A comparison of metabolic health parameters in ICSI-conceived and naturally conceived adolescents.
- Author
-
Elsner, Susanne, Katalinic, Alexander, Ludwig, Annika K, Sonntag, Barbara, Martensen, Max Johannes, Kixmüller, Dorthe, Eisemann, Nora, and Ludwig, Michael
- Subjects
- *
TEENAGERS , *TEENAGE girls , *BODY mass index , *BLOOD testing , *WAIST circumference - Abstract
Are there differences in the cardiometabolic health of ICSI-conceived adolescents compared with a control group, taking parental risk factors into account? ICSI-conceived adolescents (n = 272), their mothers (n = 273) and naturally conceived control adolescents (n = 273) and their mothers (n = 273) provided a blood test and answered a health-related questionnaire. The adolescents also attended a physical examination. ICSI-conceived males showed significantly higher mean weight (72.6 ± 15.1 versus 67.7 ± 12.6 kg, P = 0.005), body mass index (BMI) (22.2 ± 3.7 versus 21.0 ± 3.2 kg/m2, P = 0.007) and waist circumference (79.1 ± 11.6 versus 74.5 ± 8.7 cm, P < 0.001). The mean values for weight and BMI were also significantly higher in the ICSI parents. In the ICSI-conceived females significant differences in high-density lipoprotein cholesterol (1.5 ± 0.3 versus 1.6 ± 0.3 mmol/l, P = 0.033) and triglyceride values (1.1 ± 0.5 versus 1.0 ± 0.4 mmol/l, P = 0.013) were observed. ICSI mothers also had significantly higher triglycerides (P = 0.002), higher glutamate pyruvate transaminase/alanine aminotransferase (P < 0.001) and higher alkaline phosphatase values (P < 0.001). Increased values for weight were found in the male and differences in lipid parameters in the female ICSI-conceived adolescents, which were reflected in the values of their parents. Adjustment for parental risk factors generally attenuated the differences between the ICSI and the control groups, but did not completely remove them. Whether these observed differences are clinically relevant for the future health of the participants requires further study. To increase knowledge in this area, future studies should also include parental data. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
6. Comorbidities, timing of treatments, and chemotherapy use influence outcomes in stage III colon cancer: A population-based European study.
- Author
-
Minicozzi, Pamela, Vicentini, Massimo, Innos, Kaire, Castro, Clara, Guevara, Marcela, Stracci, Fabrizio, Carmona-Garcia, M a Carmen, Rodriguez-Barranco, Miguel, Vanschoenbeek, Katrijn, Rapiti, Elisabetta, Katalinic, Alexander, Marcos-Gragera, Rafael, Van Eycken, Liesbet, Sánchez, Maria José, Bielska-Lasota, Magdalena, Rossi, Paolo Giorgi, and Sant, Milena
- Subjects
COLON cancer ,CANCER chemotherapy ,COMORBIDITY ,SURGICAL emergencies ,SURGICAL diagnosis - Abstract
For stage III colon cancer (CC), surgery followed by chemotherapy is the main curative approach, although optimum times between diagnosis and surgery, and surgery and chemotherapy, have not been established. We analysed a population-based sample of 1912 stage III CC cases diagnosed in eight European countries in 2009–2013 aiming to estimate: (i) odds of receiving postoperative chemotherapy, overall and within eight weeks of surgery; (ii) risks of death/relapse, according to treatment, Charlson Comorbidity Index, time from diagnosis to surgery for emergency and elective cases, and time from surgery to chemotherapy; and (iii) time-trends in chemotherapy use. Overall, 97% of cases received surgery and 65% postoperative chemotherapy, with 71% of these receiving chemotherapy within eight weeks of surgery. Risks of death and relapse were higher for cases starting chemotherapy with delay, but better than for cases not given chemotherapy. Fewer patients with high comorbidities received chemotherapy than those with low (P < 0.001). Chemotherapy timing did not vary (P = 0.250) between high and low comorbidity cases. Electively-operated cases with low comorbidities received surgery more promptly than high comorbidity cases. Risks of death and relapse were lower for elective cases given surgery after four weeks than cases given surgery within a week. High comorbidities were always independently associated with poorer outcomes. Chemotherapy use increased over time. Our data indicate that promptly-administered postoperative chemotherapy maximizes its benefit, and that careful assessment of comorbidities is important before treatment. The survival benefit associated with slightly delayed elective surgery deserves further investigation. • Practically all stage III colon cancer cases received surgery, 65% of these received postoperative chemotherapy • Fewer high comorbidity cases received prompt elective surgery or received chemotherapy • Receiving surgery ≤4 weeks from diagnosis was associated with poorer outcomes • Starting chemotherapy >8 weeks from surgery was associated with poorer outcomes • High comorbidities were independently associated with poorer outcomes [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
7. A population-based registry study on relative survival from melanoma in Germany stratified by tumor thickness for each histologic subtype.
- Author
-
Brunssen, Alicia, Jansen, Lina, Eisemann, Nora, Waldmann, Annika, Weberpals, Janick, Kraywinkel, Klaus, Eberle, Andrea, Holleczek, Bernd, Zeissig, Sylke Ruth, Brenner, Hermann, Katalinic, Alexander, and GEKID Cancer Survival Working Group
- Abstract
Background: Differences in relative survival (RS) of melanoma between histologic subtypes were discussed to be mainly caused by tumor thickness.Objective: To investigate RS of melanoma, stratified by tumor thickness for each histologic subtype, and identify survival trends.Methods: With use of cancer registry data on melanoma cases (International Classification of Diseases, 10th Revision, codes C43.0-C43.9) diagnosed in Germany in 1997-2013, 5- and 10-year age-standardized RS stratified by histologic subtype and stratified or standardized by T stage was estimated by standard and modeled period analyses. We restricted 10-year RS analyses to patients younger than 75 years.Results: We analyzed 82,901 cases. Overall, the 5- and 10-year RS rates were 91.7% and 90.8%, respectively. Prognosis worsened with increasing T stage for all histologic subtypes, but T-stage distribution varied substantially. Survival differences by histologic subtype were strongly alleviated after adjustment for T stage but remained significant. Overall, 5-year RS increased significantly (by 3.8 percentage points) between the periods 2002-2005 and 2010-2013. This increase was no longer seen after adjustment for T stage.Limitations: Exclusion of cases on account of missing information on T stages, changes in the definition of T stages, and lack of information on screening and treatment limit our analyses.Conclusion: Differences in RS between histologic subtypes were strongly mediated by tumor thickness. Over time, RS of melanoma increased as a result of changes in T-stage distribution. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
8. Hinweise auf soziale Ungleichheit im Informationsverhalten und in der Informationsbewertung junger Frauen mit Brustkrebs – Ergebnisse der Kohortenstudie „gemeinsam gesund werden".
- Author
-
Hammersen, -->Friederike, Pursche, -->Telja, Fischer, -->Dorothea, Katalinic, -->Alexander, and Waldmann, -->Annika
- Published
- 2018
- Full Text
- View/download PDF
9. Systematic skin cancer screening in Northern Germany.
- Author
-
Breitbart, Eckhard W., Waldmann, Annika, Nolte, Sandra, Capellaro, Marcus, Greinert, Ruediger, Volkmer, Beate, and Katalinic, Alexander
- Abstract
Background: The incidence of skin cancer is increasing worldwide. For decades, opportunistic melanoma screening has been carried out to respond to this burden. However, despite potential positive effects such as reduced morbidity and mortality, there is still a lack of evidence for feasibility and effectiveness of organized skin cancer screening. Objective: The main aim of the project was to evaluate the feasibility of systematic skin cancer screening. Methods: In 2003, the Association of Dermatological Prevention was contracted to implement the population-based SCREEN project (Skin Cancer Research to Provide Evidence for Effectiveness of Screening in Northern Germany) in the German state of Schleswig-Holstein. A two-step program addressing malignant melanoma and nonmelanocytic skin cancer was implemented. Citizens (aged ≥20 years) with statutory health insurance were eligible for a standardized whole-body examination during the 12-month study period. Cancer registry and mortality data were used to assess first effects. Results: Of 1.88 million eligible citizens, 360,288 participated in SCREEN. The overall population-based participation rate was 19%. A total of 3103 malignant skin tumors were found. On the population level, invasive melanoma incidence increased by 34% during SCREEN. Five years after SCREEN a substantial decrease in melanoma mortality was seen (men: observed 0.79/100,000 and expected 2.00/100,000; women: observed 0.66/100,000 and expected 1.30/100,000). Limitations: Because of political reasons (resistance as well as lack of support from major German health care stakeholders), it was not possible to conduct a randomized controlled trial. Conclusions: The project showed that large-scale systematic skin cancer screening is feasible and has the potential to reduce skin cancer burden, including mortality. Based on the results of SCREEN, a national statutory skin cancer early detection program was implemented in Germany in 2008. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
10. A novel approach to estimate the German-wide incidence of testicular cancer
- Author
-
Stang, Andreas, Katalinic, Alexander, Dieckmann, Klaus-Peter, Pritzkuleit, Ron, and Stabenow, Roland
- Subjects
- *
TESTICULAR cancer , *EPIDEMIOLOGY of cancer , *HOSPITAL care , *CANCER diagnosis , *CASTRATION , *MEDICAL records - Abstract
Abstract: Background: Currently, only 7 out of 16 Federal States of Germany provide testicular cancer incidence rates with an estimated completeness of at least 90% which complicates the regional comparison of incidence rates. The aim of this study was to provide a novel approach to estimate the testicular cancer incidence in Germany by using nationwide hospitalization data. Methods: We used the nationwide hospitalization data (DRG statistics) of the years 2005–2006 including 16,6 million hospitalizations among men. We identified incident testicular cancer cases by the combination of a diagnosis of testicular cancer and an orchiectomy during the same hospitalization and estimated the age-specific and age-standardized (World Standard Population) incidence of testicular cancer across Federal States. We also analyzed available cancer registry data from 2005 to 2006. Results: A total of 8544 hospitalizations indicated incident testicular cancer cases in 2005–2006. The nationwide crude incidence rate of testicular cancer was 10,6 per 100.000 person-years. The ratio of the number of registered cases (cancer registry) to the estimated number of cases based on the hospitalization statistics ranged between 79% and 100%. There was only little variation of the age-standardized DRG-based incidence estimates across Federal States (range: 8,2–10,6 per 100.000 person-years). Discussion: We provided testicular cancer incidence estimates for each of the 16 Federal States of Germany based on hospitalization data for the first time. The low within-population incidence variability in Germany and high between-population incidence variability in Europe may indicate that ecologic factors play a causal role in the European variation of testicular cancer. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
11. Neuromotor development and mental health at 5.5 years of age of singletons born at term after intracytoplasmatic sperm injection ICSI: results of a prospective controlled single-blinded study in Germany
- Author
-
Ludwig, Annika, Katalinic, Alexander, Thyen, Ute, Sutcliffe, Alastair G., Diedrich, Klaus, and Ludwig, Michael
- Subjects
- *
MENTAL health , *HUMAN in vitro fertilization , *MOTOR ability in children , *DEVELOPMENTAL neurobiology , *HEALTH outcome assessment , *MOTOR neurons , *CHILD psychology , *INTELLECT , *LONGITUDINAL method - Abstract
Objective: To assess the neurodevelopmental health of children born after intracytoplasmatic sperm injection (ICSI). Design: Prospective controlled blinded study. Setting: Tertiary care center. Patient(s): A total of 276 term-born singletons conceived by ICSI and 273 matched spontaneously conceived (SC) singletons at the age of 5.5 years. Main Outcome Measure(s): Neuromotor development assessed by a detailed neurologic examination, including the standardized motor test MOT 4–6, and emotional/behavioral development and intelligence assessed with the Kaufman-Assessment Battery for Children. Result(s): There were no significant differences between ICSI children and control children regarding the neurologic examination, motor skills, emotional/behavioral development, and intelligence. Conclusion(s): The ICSI children born at term develop normally, similar to SC children. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
12. Physical health at 5.5 years of age of term-born singletons after intracytoplasmic sperm injection: results of a prospective, controlled, single-blinded study
- Author
-
Ludwig, Annika K., Katalinic, Alexander, Thyen, Ute, Sutcliffe, Alastair G., Diedrich, Klaus, and Ludwig, Michael
- Subjects
- *
HUMAN in vitro fertilization , *CHILDREN'S health , *HEALTH outcome assessment , *JUVENILE diseases , *HOSPITAL care of children , *PEDIATRIC surgery , *CHRONICALLY ill children , *BIOMETRY - Abstract
Objective: To study the health of children born after ICSI and of spontaneously conceived control children at the age of 4–6 years. Design: Prospective, controlled, blinded study. Setting: Tertiary-care center. Patient(s): Two hundred seventy-six term-born singletons conceived by ICSI and 273 matched spontaneously conceived singletons at the age of 5.5 years. Intervention(s): Detailed physical examination, interview of the parents, and collection of data from each child''s examination booklet. Main Outcome Measure(s): Biometrical data; current health status; acute, chronic and childhood illnesses; hospitalizations; and surgeries. Result(s): Detailed physical examination did not reveal any relevant differences between ICSI and spontaneously conceived children. There were no relevant differences regarding the incidence of childhood illnesses, acute or chronic illnesses, accidents, and surgeries up to the age of 5.5 years. However, a history of undescended testicles was found significantly more often in boys born after ICSI (5.4% vs. 0.7%), with the consequence that they had significantly more urogenital surgery (19.2% vs. 8.9%). Significantly more ICSI children had been hospitalized (37.6% vs. 27.2%), although we did not find any specific reason for the increased hospitalization rate. Conclusion(s): Other than an increased risk of undescended testicles and therefore an increase in urogenital surgeries in ICSI boys, the physical health of ICSI children was comparable to that of spontaneously conceived children at the age of 5.5 years. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
13. Pregnancy course and outcome after intracytoplasmic sperm injection: a controlled, prospective cohort study
- Author
-
Katalinic, Alexander, Rösch, Christine, and Ludwig, Michael
- Subjects
- *
REPRODUCTION , *PREGNANCY , *NEWBORN infants , *GESTATIONAL age - Abstract
Objective: To determine pregnancy course and major malformation rate after intracytoplasmic sperm injection (ICSI).Design: Prospective, controlled, multicenter, nationwide German cohort study.Setting: Tertiary infertility centers in Germany.Patient(s): Three thousand three hundred seventy-two children and fetuses and 8,016 children and fetuses after the 16th week of gestation in pregnancies after ICSI and natural conception, respectively.Intervention(s): Standardized prospective follow-up.Main outcome measure(s): Major malformation rate.Result(s): The major malformation rate was 8.7% (295/3,372) for the ICSI cohort and 6.1% (488/8,016) for the population-based control cohort (relative risk, 1.44 [1.25–1.65]). After adjustment for risk factors, the risk declined (adjusted odds ratio, 1.24 [95% CI, 1.02–1.50]). Regarding singletons, there was a significant difference for birth weight and gestational age, with a higher number of preterm and low birth weight children in pregnancies achieved after ICSI.Conclusion(s): Children who are born after intracytoplasmic sperm injection have an increased risk of a major congenital malformation compared with those born after spontaneous conception. This risk is mainly due to paternal and maternal risk factors, which are more prevalent in couples who use ICSI for reproduction. An infertility-linked risk is highly probable for the observed findings. A technique-related risk, however, cannot be ruled out. [Copyright &y& Elsevier]
- Published
- 2004
- Full Text
- View/download PDF
14. Can we sense ART? The blinded examiner is not blind—a problem with follow-up studies on children born after assisted reproduction
- Author
-
Ludwig, Annika K., Katalinic, Alexander, Entenmann, Andreas, Thyen, Ute, Sutcliffe, Alastair G., Diedrich, Klaus, and Ludwig, M.
- Subjects
- *
HUMAN reproductive technology , *CHILDREN'S health , *LONGITUDINAL method , *CONCEPTION , *INTUITION , *SPERMATOZOA , *HEALTH outcome assessment , *COMPUTERS in medicine - Abstract
In a prospective, controlled, blinded follow-up study of children born after intracytoplasmic sperm injection (ICSI), blinded examiners correctly intuited the mode of conception (ICSI versus spontaneous) in three out of four children, which must be considered when interpreting outcome data for children born after assisted reproduction. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
15. Complete cancer prevalence in Europe in 2020 by disease duration and country (EUROCARE-6): a population-based study.
- Author
-
De Angelis, Roberta, Demuru, Elena, Baili, Paolo, Troussard, Xavier, Katalinic, Alexander, Chirlaque Lopez, Maria Dolores, Innos, Kaire, Santaquilani, Mariano, Blum, Marcel, Ventura, Leonardo, Paapsi, Keiu, Galasso, Rocco, Guevara, Marcela, Randi, Giorgia, Bettio, Manola, Botta, Laura, Guzzinati, Stefano, Dal Maso, Luigino, and Rossi, Silvia
- Subjects
- *
DISEASE duration , *NOSOLOGY , *RENAL cancer , *BLADDER cancer , *BLADDER , *THYROID cancer , *CANCER fatigue - Abstract
Cancer survivors—people living with and beyond cancer—are a growing population with different health needs depending on prognosis and time since diagnosis. Despite being increasingly necessary, complete information on cancer prevalence is not systematically available in all European countries. We aimed to fill this gap by analysing population-based cancer registry data from the EUROCARE-6 study. In this population-based study, using incidence and follow-up data up to Jan 1, 2013, from 61 cancer registries, complete and limited-duration prevalence by cancer type, sex, and age were estimated for 29 European countries and the 27 countries in the EU (EU27; represented by 22 member states that contributed registry data) using the completeness index method. We focused on 32 malignant cancers defined according to the third edition of the International Classification of Diseases for Oncology, and only the first primary tumour was considered when estimating the prevalence. Prevalence measures are expressed in terms of absolute number of prevalent cases, crude prevalence proportion (reported as percentage or cases per 100 000 resident people), and age-standardised prevalence proportion based on the European Standard Population 2013. We made projections of cancer prevalence proportions up to Jan 1, 2020, using linear regression. In 2020, 23 711 thousand (95% CI 23 565–23 857) people (5·0% of the population) were estimated to be alive after a cancer diagnosis in Europe, and 22 347 thousand (95% CI 22 210–22 483) in EU27. Cancer survivors were more frequently female (12 818 thousand [95% CI 12 720–12 917]) than male (10 892 thousand [10 785–11 000]). The five leading tumours in female survivors were breast cancer, colorectal cancer, corpus uterine cancer, skin melanoma, and thyroid cancer (crude prevalence proportion from 2270 [95%CI 2248–2292] per 100 000 to 301 [297–305] per 100 000). Prostate cancer, colorectal cancer, urinary bladder cancer, skin melanoma, and kidney cancer were the most common tumours in male survivors (from 1714 [95% CI 1686–1741] per 100 000 to 255 [249–260] per 100 000). The differences in prevalence between countries were large (from 2 to 10 times depending on cancer type), in line with the demographic structure, incidence, and survival patterns. Between 2010 and 2020, the number of prevalent cases increased by 3·5% per year (41% overall), partly due to an ageing population. In 2020, 14 850 thousand (95% CI 14 681–15 018) people were estimated to be alive more than 5 years after diagnosis and 9099 thousand (8909–9288) people were estimated to be alive more than 10 years after diagnosis, representing an increasing proportion of the cancer survivor population. Our findings are useful at the country level in Europe to support evidence-based policies to improve the quality of life, care, and rehabilitation of patients with cancer throughout the disease pathway. Future work includes estimating time to cure by stage at diagnosis in prevalent cases. European Commission. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
16. Impact of skin cancer screening and secondary prevention campaigns on skin cancer incidence and mortality: A systematic review.
- Author
-
Brunssen, Alicia, Waldmann, Annika, Eisemann, Nora, and Katalinic, Alexander
- Abstract
Background Benefits of skin cancer screening remain controversial. Objective We sought to update evidence on the impact of skin cancer screening and secondary prevention campaigns on skin cancer incidence, mortality, stage-specific incidence, and interval cancers after negative screening. Methods We searched MEDLINE and EMBASE for studies published in English or German between January 1, 2005, and February 4, 2015. Two reviewers independently performed study selection, data extraction, and critical appraisal. Results were described in a narrative synthesis. Results Of 2066 records identified in databases and 10 records found by manual search, we included 15 articles. Overall, evidence suggests that with implementation of skin cancer screening, incidence of in situ and invasive skin cancer increased; increasing rates of thin and decreasing rates of thick melanoma were observed. After cessation of screening, invasive melanoma incidence decreased. A significant melanoma mortality reduction was shown in a German study; 2 other studies observed fewer deaths than expected. No study on interval cancers was identified. Limitations Publication bias cannot be ruled out. Most studies are limited because of their ecological design. Conclusion Large ecological studies, a cohort study, a case-control study, and a survey indicate benefits of skin cancer screening, but the evidence level is very low. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
17. Impact of skin cancer screening and secondary prevention campaigns on skin cancer incidence and mortality: A systematic review.
- Author
-
Brunssen, Alicia, Waldmann, Annika, Eisemann, Nora, and Katalinic, Alexander
- Abstract
Background: Benefits of skin cancer screening remain controversial.Objective: We sought to update evidence on the impact of skin cancer screening and secondary prevention campaigns on skin cancer incidence, mortality, stage-specific incidence, and interval cancers after negative screening.Methods: We searched MEDLINE and EMBASE for studies published in English or German between January 1, 2005, and February 4, 2015. Two reviewers independently performed study selection, data extraction, and critical appraisal. Results were described in a narrative synthesis.Results: Of 2066 records identified in databases and 10 records found by manual search, we included 15 articles. Overall, evidence suggests that with implementation of skin cancer screening, incidence of in situ and invasive skin cancer increased; increasing rates of thin and decreasing rates of thick melanoma were observed. After cessation of screening, invasive melanoma incidence decreased. A significant melanoma mortality reduction was shown in a German study; 2 other studies observed fewer deaths than expected. No study on interval cancers was identified.Limitations: Publication bias cannot be ruled out. Most studies are limited because of their ecological design.Conclusion: Large ecological studies, a cohort study, a case-control study, and a survey indicate benefits of skin cancer screening, but the evidence level is very low. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
18. M1154 Uncomplicated Long-Term Course of Crohn's Disease Can Be Predicted.
- Author
-
Kruis, Wolfgang, Katalinic, Alexander, Klugmann, Tobias, Franke, Gerd-Ruediger, Weismueller, Josef, Ceplis-Kastner, Sabine, Reimers, Birgitta, and Bokemeyer, Bernd
- Published
- 2009
- Full Text
- View/download PDF
19. T2094 Investigation of the Colorectal Cancer Susceptibility Region On Chromosome 8q24.21 in a Large German Patient Sample.
- Author
-
Schafmayer, Clemens, Buch, Stephan, Völzke, Henry Völzke, Egberts, Jan H., Schniewind, Bodo, Brosch, Mario, Ruether, Andreas, Sipos, Bence, Hellmig, Stephan, Katalinic, Alexander, Lerch, Markus M., John, Ulrich, Fölsch, Ulrich R., Faendrich, Fred, Kalthoff, Holger, Krawczak, Michael, Schreiber, Stefan, Tepel, Juergen, and Hampe, Jochen
- Published
- 2008
- Full Text
- View/download PDF
20. Effects of additional telemedicine care on mortality and cardiac morbidity in patients with coronary artery disease — The TeleGuard-RCT
- Author
-
Waldmann, Annika, Katalinic, Alexander, Schwaab, Bernhard, Sheikhzadeh, Abdolhamid, and Raspe, Heiner
- Published
- 2007
- Full Text
- View/download PDF
21. Survival of European adolescents and young adults diagnosed with cancer in 2010–2014.
- Author
-
Trama, Annalisa, Botta, Laura, Stiller, Charles, Visser, Otto, Cañete-Nieto, Adela, Spycher, Ben, Bielska-Lasota, Magdalena, Katalinic, Alexander, Vener, Claudia, Innos, Kaire, Marcos-Gragera, Rafael, Paapsi, Keiu, Guevara, Marcela, Demuru, Elena, Mousavi, Seyed Mohsen, Blum, Marcel, Eberle, Andrea, Ferrari, Andrea, Bernasconi, Alice, and Lasalvia, Paolo
- Subjects
- *
TUMOR diagnosis , *SURVIVAL rate , *HEMATOLOGIC malignancies , *CANCER patients , *DESCRIPTIVE statistics , *CENTRAL nervous system , *REPORTING of diseases , *LYMPHOBLASTIC leukemia , *ADOLESCENCE , *ADULTS - Abstract
We used the comprehensive definition of AYA (age 15 to 39 years) to update 5-year relative survival (RS) estimates for AYAs in Europe and across countries and to evaluate improvements in survival over time. We used data from EUROCARE-6. We analysed 700,000 AYAs with cancer diagnosed in 2000–2013 (follow-up to 2014). We focused the analyses on the 12 most common cancers in AYA. We used period analysis to estimate 5-year RS in Europe and 5-year RS differences in 29 countries (2010–2014 period estimate) and over time (2004–06 vs. 2010–14 period estimates). 5-year RS for all AYA tumours was 84%, ranging from 70% to 90% for most of the 12 tumours analysed. The exceptions were acute lymphoblastic leukaemia, acute myeloid leukaemia, and central nervous system tumours, presenting survival of 59%, 61%, and 62%, respectively. Differences in survival were observed among European countries for all cancers, except thyroid cancers and ovarian germ-cell tumours. Survival improved over time for most cancers in the 15- to 39-year-old age group, but for fewer cancers in adolescents and 20- to 29-year-olds. This is the most comprehensive study to report the survival of 12 cancers in AYAs in 29 European countries. We showed variability in survival among countries most likely due to differences in stage at diagnosis, access to treatment, and lack of referral to expert centres. Survival has improved especially for haematological cancers. Further efforts are needed to improve survival for other cancers as well, especially in adolescents. • Tumours of adolescents and young adults can be treated effectively. • Application of paediatric protocols to AYAs with ALL improves outcomes. • We highlighted survival differences between European countries for most AYA tumours. • Survival improved over time for most cancers in the 15- to 39-year-old age group. • Survival improved over time for fewer cancers in those aged 15 to 29. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
22. Incidence patterns and trends of malignant gonadal and extragonadal germ cell tumors in Germany, 1998-2008.
- Author
-
Rusner, Carsten, Trabert, Britton, Katalinic, Alexander, Kieschke, Joachim, Emrich, Katharina, and Stang, Andreas
- Subjects
- *
GERMPLASM , *SPERMATOGENESIS , *EMBRYOLOGY , *OOGENESIS , *HEREDITY - Abstract
Background: Malignant gonadal (GGCT) and extragonal germ cell tumors [GCT (EGCT)] are thought to originate from primordial germ cells. In contrast to well reported population-based data of GGCTs in males, analyses of GGCTs in females and EGCTs in both sexes remain limited. Methods: In a pooling project of nine population-based cancer registries in Germany for the years 1998- 2008, 16,883 malignant GCTs and their topographical sites were identified using ICD-O morphology and topography for persons aged 15 years and older. We estimated age-specific and age-standardized incidence rates. Results: Among males, the incidence of testicular GCTs increased over time. In contrast, there was no increase in the incidence of EGCTs. Among females, rates of ovarian GCTs were stable, while rates of EGCTs declined over time. The most frequent extragonadal sites were mediastinum among males and placenta among females. Conclusions: Our results underline different incidence trends and distinct age-specific incidence patterns of malignant GGCTs and EGCTs, as reported recently by several population-based registries. The differences suggest that GGCT and EGCT may have different etiologies. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
23. Cutaneous melanoma attributable to UVR exposure in Denmark and Germany.
- Author
-
Keim, Ulrike, Gandini, Sara, Amaral, Teresa, Katalinic, Alexander, Holleczek, Bernd, Flatz, Lukas, Leiter, Ulrike, Whiteman, David, and Garbe, Claus
- Subjects
- *
MELANOMA , *SKIN tumors - Abstract
Increasing incidence rates of cutaneous melanoma (CM) observed during the last five decades in white populations are largely attributed to increased exposure to solar ultraviolet radiation (UVR), often expressed as population attributable fraction (PAF). Thus, many CMs could be prevented by reducing UVR exposure. The aim of this study was to estimate the PAF of CM attributable to UVR exposure and demographic changes in Denmark and Saarland/Germany for the period 1943 to 2036. CM incidence data (ICD-10, C43) for Denmark (1943–2016) and the German Federal State of Saarland (1972–2016) were retrieved from the NORDCAN database and from the Saarland Cancer Registry. The number of CMs attributable to UVR exposure was calculated by comparing contemporary or predicted CM incidence rates with CM rates in Denmark during the years 1943–1946. In Denmark, the proportion of CM cases attributable to UVR exposure increased from around 20% in 1947–1951 to 96% in 2012–2016; in the Federal State of Saarland, it increased from 50% in 1972–1976 to 90% in 2012–2016. Until 2032–2036, the PAF is expected to rise in Denmark to 97% and in the Saarland to 92%. The demographic influence, on the other hand, is rather small. More than 90% of all CM in Germany and Denmark are attributable to UVR exposure, and in principle, preventable. These findings underline the need for primary prevention strategies, aiming to increase the awareness of melanoma and its risk factors and to promote behavioural changes that decrease sun exposure. • Long-term estimates of UVR-related CM burden in Denmark and Germany from 1943 to 2036. • In 2012–2016, over 90% of CM cases in Denmark and Germany were attributable to UVR. • Increasing UVR-related CM burden is to be expected if risk behaviour does not change. • Primary prevention focusing on reducing UVR exposure is crucial for CM control. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
24. Comparison of cryopreservation outcome with gonadotropin-releasing hormone agonists or antagonists in the collecting cycle
- Author
-
Seelig, Anna Sophie, Al-Hasani, Safa, Katalinic, Alexander, Schöpper, Beate, Sturm, Rita, Diedrich, Klaus, Ludwig, Michael, and Schöpper, Beate
- Subjects
- *
PREGNANCY , *GONADOTROPIN , *GONADOTROPIN releasing hormone , *BIRTH rate , *COMPARATIVE studies , *CRYOPRESERVATION of organs, tissues, etc. , *EMBRYO transfer , *FERTILIZATION in vitro , *FOLLICLE-stimulating hormone , *HORMONE antagonists , *RESEARCH methodology , *MEDICAL cooperation , *INDUCED ovulation , *OVUM , *RECOMBINANT proteins , *RESEARCH , *EVALUATION research , *RETROSPECTIVE studies - Abstract
Objective: To compare the pregnancy rates of frozen-thawed 2-pronucleate (2PN) oocytes obtained either in a long protocol or in an antagonist protocol and ovarian stimulation with either human menopausal gonadotropin (hMG) or recombinant follicular stimulating hormone (recFSH).Design: Retrospective data analysis.Setting: Academic infertility center.Patient(s): Three hundred forty-two infertile couples who underwent a transfer of cryopreserved 2PN oocytes.Intervention(s): hMG (n = 194) or recFSH (n = 92) in a long protocol or hMG (n = 16) or recFSH (n = 40) stimulation under pituitary suppression with the GnRH antagonist Cetrotide was used. The 2PN oocytes were transferred after endometrial preparation using E(2) valerate and vaginal progesterone (Crinone 8% vaginal gel).Main Outcome Measure(s): Implantation, pregnancy, and abortion rates.Result(s): Implantation rates in the freeze-thaw cycles were 5.6% (hMG) and 3.8% (recFSH) with 2PN oocytes from the long protocol and 7% from the antagonist cycles, irrespective of whether hMG or recFSH was used. Pregnancy rates were similar independent of whether they resulted from the long-protocol cycles with hMG (15.4%) and recFSH (13.1%) or from the antagonist protocol cycles with hMG (25.0%) and recFSH (17.5%).Conclusion(s): The potential to implant is independent of the gonadotropin-releasing hormone analogue and gonadotropin chosen for the collection cycle when previously cryopreserved 2PN oocytes were replaced after thawing in the cleavage stage. [ABSTRACT FROM AUTHOR]- Published
- 2002
- Full Text
- View/download PDF
25. Epidemiology of cutaneous melanoma and keratinocyte cancer in white populations 1943–2036.
- Author
-
Garbe, Claus, Keim, Ulrike, Gandini, Sara, Amaral, Teresa, Katalinic, Alexander, Hollezcek, Bernd, Martus, Peter, Flatz, Lukas, Leiter, Ulrike, and Whiteman, David
- Subjects
- *
MELANOMA , *MORTALITY , *DISEASE incidence , *SKIN tumors , *WHITE people , *KERATINOCYTES , *LONGITUDINAL method - Abstract
Cutaneous melanoma (CM) and keratinocyte cancer (KC) cause considerable morbidity and mortality. We analysed long-term trends of CM and KC in different white populations. Age-standardised (European Standard Population 2013) incidence and mortality rates (ASIR, ASMR) of CM were extracted from cancer registries in Denmark, New Zealand and the US SEER-Database. ASIRs of KC were sourced from registries of the German federal states Saarland and Schleswig–Holstein, and from Scotland. Age-period-cohort models were used to project melanoma incidence trends. In Denmark between 1943 and 2016, melanoma ASIR increased from 1.1 to 46.5 in males, and from 1.0 to 48.5 in females, estimated to reach 60.0 and 73.1 in males and females by 2036. Melanoma mortality in Denmark (1951–2016) increased from 1.4 to 6.7 (males) and 1.2 to 3.7 (females). In New Zealand between 1948 and 2016, ASIR increased from 2.7 to 81.0 (males) and from 3.8 to 54.7 (females), slight declines are estimated by 2036 for both genders. Melanoma mortality increased six-fold in New Zealand males between 1950 and 2016; smaller increases were observed in females. We observed three- to four-fold increases in melanoma incidence in US whites, predicted to rise to 56.1 and 36.2 in males and females until 2036. Melanoma mortality also increased among US whites between 1970 and 2017, female melanoma mortality remained stable. Similar trends are shown for KC. In white populations, incidence of CM and KC significantly increased. CM incidence continues to rise in the short term but is predicted to decline in future. • Cutaneous melanoma (CM) incidence 73 years of observation and 20 years of projection. • Incidence increase of CM 15–48 times. • Similar trends in keratinocyte cancer. • Age standardised with European standard population 2013 instead of crude rates. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
26. Survival for patients with rare haematologic malignancies: Changes in the early 21st century.
- Author
-
Pulte, Dianne, Weberpals, Janick, Jansen, Lina, Luttmann, Sabine, Holleczek, Bernd, Nennecke, Alice, Ressing, Meike, Katalinic, Alexander, and Brenner, Hermann
- Subjects
- *
LEUKEMIA , *LYMPHOMAS , *B cell lymphoma , *CHRONIC myeloid leukemia , *HEMATOLOGIC malignancies , *MYCOSIS fungoides , *RARE diseases , *CANCER patients , *DATABASES , *REPORTING of diseases , *HEALTH , *SURVIVAL analysis (Biometry) , *DESCRIPTIVE statistics , *PROGNOSIS - Abstract
Introduction Population-level survival has improved for common haematologic malignancies in the early 21st century. However, relatively few population-level data are available for rare haematologic malignancies. Methods Data were extracted from 12 cancer registries in Germany and the Surveillance, Epidemiology and End Results database in the United States (US). Cases of haematologic malignancies with an incidence of less than 1 per 100,000 were selected for analysis. Period analysis was used to determine 5-year relative survival (RS) for the years 2003–2012, and modelled period analysis was used to determine changes in survival between 2003–2007 and 2008–2012. Results Seven individual haematologic malignancies which met criteria were identified. Overall 5-year age-adjusted RS was 62.4% in Germany and 57.0% in the US in 2003–2012, with a good deal of variability by individual haematologic malignancy, ranging from less than 30% for chronic monomyeloid leukaemia to greater than 85% for hairy cell leukaemia and mycosis fungoides. Five-year RS increased significantly between 2003–2007 and 2008–2012 for patients with mantle cell lymphoma, Burkitt's lymphoma and hairy cell leukaemia in Germany and for patients with mantle cell lymphoma and anaplastic large-cell kinase+ anaplastic lymphoma in the US. Conclusions Survival for rare haematologic malignancies varied considerably by cancer entity. Overall 5-year RS was slightly higher in Germany compared to the US. Survival estimates increased for a minority of haematologic malignancies between 2003–2007 and 2008–2012. Further research into the best treatment options for rare malignancies is needed to further improve survival. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
27. Cancer in Europe: Death sentence or life sentence?
- Author
-
Liu, Lifang, O'Donnell, Peter, Sullivan, Richard, Katalinic, Alexander, Moser, Lotte, de Boer, Angela, and Meunier, Francoise
- Subjects
- *
CANCER patient psychology , *EMPLOYMENT discrimination , *MEETINGS , *SOCIAL adjustment , *SOCIAL stigma , *TUMORS in children - Abstract
With so many adults and children receiving successful treatment for their cancer, survivorship is now a ‘new’ and critical issue. It is increasingly recognised that the growing numbers of survivors face new challenges in their bid to return to ‘normal’ life. What is not yet so widely recognised is the need for a broad response to help them cope—with stigmatisation, misunderstanding, lifelong issues of confidence and social adaptation, and even access to employment and to financial services. As a further stage in its programme of attention to this aspect of cancer, the European Organisation for Research and Treatment of Cancer (EORTC) brought survivors, researchers, carers, authorities and policymakers together at a meeting in Brussels in March/April 2016, to learn at first hand about the posttreatment experience of cancer survivors. The meeting demonstrated that while research is well advanced in many of the medical consequences of survivorship, understanding is still lacking of many non-clinical, personal and administrative issues. The meeting raised the discussion of survivorship research beyond the individual to a population-based approach, exploring the related socioeconomic issues. Its exploration of initiatives across Europe countries provoked new thinking on the need for effective collaboration, with a new focus on non-clinical issues, including effective dialogue with financial service providers and employers, improvements in collecting, exchanging and accessing data, and above all, ways of translating research outcomes into action. This will require wider recognition that, as Françoise Meunier, Director Special Projects, EORTC, said, ‘It is time for a new mind set’. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
28. Survival of elderly patients with multiple myeloma—Effect of upfront autologous stem cell transplantation.
- Author
-
Merz, Maximilian, Jansen, Lina, Castro, Felipe A., Hillengass, Jens, Salwender, Hans, Weisel, Katja, Scheid, Christof, Luttmann, Sabine, Emrich, Katharina, Holleczek, Bernd, Katalinic, Alexander, Nennecke, Alice, Straka, Christian, Langer, Christian, Engelhardt, Monika, Einsele, Hermann, Kröger, Nicolaus, Beelen, Dietrich, Dreger, Peter, and Brenner, Hermann
- Subjects
- *
MULTIPLE myeloma treatment , *AUTOGRAFTS , *HEMATOPOIETIC stem cell transplantation , *SURVIVAL , *OLD age - Abstract
Background The aim of this study was to determine the value of upfront autologous transplantation (ASCT) in elderly patients (60–79 years) with myeloma. Methods We analysed relative survival (RS) of patients diagnosed in 1998–2011 and treated with ASCT within 12 months after diagnosis in Germany (n = 3591; German Registry of Stem Cell Transplantation) and compare RS with survival of myeloma patients diagnosed in the same years in Germany (n = 13,903; population-based German Cancer Registries). Results Utilisation of ASCT has increased rapidly between 2000–2002 and 2009–2011 (60–64years: 7.0–43.0%; 65–69 years: 6.6–23.7%; 70–79 years: 0.4–4.0%). Comparison of 5-year RS of patients from the general German myeloma population who have survived the first year after diagnosis with 5-year RS of patients treated with ASCT revealed higher survival for transplanted patients among all age groups (60–64: 59.2% versus 66.1%; 65–69: 57.4% versus 61.7%; 70–79: 51.0% versus 56.6%). RS increased strongly between 2003–2005 and 2009–2011 for the general German myeloma population (+8.5%) and for patients treated with ASCT (+11.8%). Differences in RS between these groups increased over time from +1.9% higher age-standardised survival in transplanted patients in 2003–2005 to 5.2% higher survival in 2009–2011. Conclusion We conclude that upfront ASCT might be a major contributor to improved survival for elderly myeloma patients in Germany. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
29. Death certificate only proportions should be age adjusted in studies comparing cancer survival across populations and over time.
- Author
-
Brenner, Hermann, Castro, Felipe A., Eberle, Andrea, Emrich, Katharina, Holleczek, Bernd, Katalinic, Alexander, and Jansen, Lina
- Subjects
- *
AGE distribution , *CANCER patients , *SURVIVAL analysis (Biometry) , *DEATH certificates - Abstract
Background: The proportion of cases notified by death certificate only (DCO) is a commonly used data quality indicator in studies comparing cancer survival across regions and over time. We aimed to assess dependence of DCO proportions on the age structure of cancer patients. Methods: Using data from a national cancer survival study in Germany, we determined age specific and overall (crude) DCO proportions for 24 common forms of cancer. We then derived overall (crude) DCO proportions expected in case of shifts of the age distribution of the cancer populations by 5 and 10 years, respectively, assuming age specific DCO proportions to remain constant. Results: Median DCO proportions across the 24 cancers were 2.4, 3.7, 5.5, 8.5 and 23.9% in age groups 15-44, 45-54, 55-64, 65-74, and 75+, respectively. A decrease of ages by 5 and 10 years resulted in decreases of cancer specific crude DCO proportions ranging from 0.4 to 4.8 and from 0.7 to 8.6 percent units, respectively. Conversely, an increase of ages by 5 and 10 years led to increases of cancer specific crude DCO proportions ranging from 0.8 to 4.8 and from 1.8 to 9.6 percent units, respectively. These changes were of similar magnitude (but in opposite direction) as changes in crude 5-year relative survival resulting from the same shifts in age distribution. Conclusions: The age structure of cancer patient populations has a substantial impact on DCO proportions. DCO proportions should therefore be age adjusted in comparative studies on cancer survival across regions and over time. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
30. Lung cancer survival in Germany: A population-based analysis of 132,612 lung cancer patients.
- Author
-
Eberle, Andrea, Jansen, Lina, Castro, Felipe, Krilaviciute, Agne, Luttmann, Sabine, Emrich, Katharina, Holleczek, Bernd, Nennecke, Alice, Katalinic, Alexander, and Brenner, Hermann
- Subjects
- *
LUNG cancer treatment , *CANCER-related mortality , *HISTOLOGY , *CANCER invasiveness , *MEDICAL registries - Abstract
Objectives Lung cancer is the most common cancer-related death worldwide. In Germany it accounts for 25% of cancer deaths in men, and 14% in women. The aim of this study is to provide an overview of 5-year relative survival by sex, age, histology, and tumour stage in Germany representing a population of 26.7 million people. Materials and methods The study is based on a pooled German dataset including data from 12 population-based cancer registries covering around one third of the German population. A total of 132,612 patients diagnosed with lung cancer from 2002 to 2010 were included in the analysis. Survival estimates for the time period 2007–2010 were calculated using period analysis. Differences in survival between sexes were tested for statistical significance by model-based period analysis (poisson regression model). The relative excess risk (RER) of death (women vs. men) was extracted from the model with the p value for the difference in RER. Results The overall age adjusted 5-year relative survival was 15.5% (standard error (SE) 0.2) for men and 20.3% (SE 0.3) in women. Survival differed markedly according to age (men: <60 years 18.5% vs. 80+ years 8.4% and women 23.7% vs. 10.6%, respectively), histology (largest difference between histological groups: men 25.7 and women 44.4% points) and stage (men: UICC Ia 62.9%, vs. UICC IV 4.6% and women 75.2% vs. 7.0%, respectively). Our study showed survival advantages for women compared to men, most notably in younger aged patients (RER 0.83, p < 0.0001), patients with adenocarcinoma (RER 0.80, p < 0.0001), and patients with lower stage cancer (RER 0.62, p < 0.0001). Conclusions This study presents up-to-date survival estimates for lung cancer in Germany. Compared to other European countries survival was relatively high. Women showed higher survival than men independent of age, histology and stage. The reasons for the survival differences require further clarification. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
31. Survival of women with cancers of breast and genital organs in Europe 1999-2007: Results of the EUROCARE-5 study.
- Author
-
Sant, Milena, Chirlaque Lopez, Maria Dolores, Agresti, Roberto, Sánchez Pérez, Maria José, Holleczek, Bernd, Bielska-Lasota, Magdalena, Dimitrova, Nadya, Innos, Kaire, Katalinic, Alexander, Langseth, Hilde, Larrañaga, Nerea, Rossi, Silvia, Siesling, Sabine, and Minicozzi, Pamela
- Subjects
- *
BREAST tumors , *CANCER patients , *REPORTING of diseases , *FEMALE reproductive organ tumors , *HEALTH services accessibility , *LONGITUDINAL method , *SURVIVAL analysis (Biometry) , *SURVIVAL , *TUMORS , *WOMEN'S health , *HEALTH equity - Abstract
Background: Survival differences across Europe for patients with cancers of breast, uterus, cervix, ovary, vagina and vulva have been documented by previous EUROCARE studies. In the present EUROCARE-5 study we update survival estimates and investigate changes in country-specific and over time survival, discussing their relationship with incidence and mortality dynamics for cancers for which organised screening programs are ongoing. Methods: We analysed cases archived in over 80 population-based cancer registries in 29 countries grouped into five European regions. We used the cohort approach to estimate 5-year relative survival (RS) for adult (≥15 years) women diagnosed 2000-2007, by age, country and region; and the period approach to estimate time trends (1999-2007) in RS for breast and cervical cancers. Results: In 2000-2007, 5-year RS was 57% overall, 82% for women diagnosed with breast, 76% with corpus uteri, 62% with cervical, 38% with ovarian, 40% with vaginal and 62% with vulvar cancer. Survival was low for patients resident in Eastern Europe (34% ovary-74% breast) and Ireland and the United Kingdom [Ireland/UK] (31-79%) and high for those resident in Northern Europe (41-85%) except Denmark. Survival decreased with advancing age: markedly for women with ovarian (71% 15-44 years; 20% ≥75 years) and breast (86%; 72%) cancers. Survival for patients with breast and cervical cancers increased from 1999-2001 to 2005-2007, remarkably for those resident in countries with initially low survival. Conclusions: Despite increases over time, survival for women's cancers remained poor in Eastern Europe, likely due to advanced stage at diagnosis and/or suboptimum access to adequate care. Low survival for women living in Ireland/UK and Denmark could indicate late detection, possibly related also to referral delay. Poor survival for ovarian cancer across the continent and over time suggests the need for a major research effort to improve prognosis for this common cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
32. Less pitfalls and variation in population based cancer survival comparisons within the European Union: Lessons from colorectal cancer patients in neighbouring regions in Denmark and Germany – The Fehmarn Belt project.
- Author
-
Storm, Hans H., Engholm, Gerda, Pritzkuleit, Ron, Kejs, Anne Mette T., Katalinic, Alexander, Dunst, Jürgen, and Holländer, Niels H.
- Subjects
- *
COLON tumors , *SURVIVAL , *DESCRIPTIVE statistics ,RECTUM tumors - Abstract
Background International comparisons of cancer registry based survival are often used as a marker of the performance of health care services on cancer. These are debated for comparability, validity and lack of detail with respect to prognostic factors. With a view to cross border collaborative cancer research and care in the European Union (EU), we used the established routine registration systems for cancer in the neighbouring regions Zealand, Denmark, and Schleswig-Holstein, Germany, to study if available routine registration suffices for the study of diagnosis, treatment and follow-up for colorectal cancer patients. The aim was to assess to which extent differences in survival between the regions could be explained. Methods Colorectal cancer patients recorded 2004–2010 in Schleswig-Holstein (colon: 10,631; rectum 5683) and region Zealand (colon: 3205; rectum 1747) were studied. Excluding cases aged 90+ or only known from death certificates, one- and four-year relative survival by stage for the periods 2004–2006 and 2007–2009 (one-year) were calculated. Findings A high proportion of patients in Schleswig-Holstein were known only from death certificates (colon 11%; rectum 6.9%) compared to <0.3% in region Zealand. Colon cancer incidence (asr-e) (men 36; women 28) and mortality (men 12; women 8.7) in Schleswig-Holstein were 10 per 100,000 lower than in Zealand; minor differences were seen for rectum cancer. One and four-year overall survival increased in both regions but was superior in Schleswig-Holstein. For patients with reported stage I–III, negligible differences in survival were seen; with further restriction to patients with treatment reported, even so in stage IV patients 2007–2009. Interpretation Improved data quality and comparability than presently used in the large international survival studies is needed. If stage and treatment is taken into account, more valid international comparisons of cancer survival are possible. Reporting and follow-up must be improved and cases only known from death certificates (DCO) minimised. A high proportion DCO (excluded from analyses) may produce higher survival, whereas a low the opposite. Co-morbidity and socio-economic status should be included alongside other prognostic variables in survival studies. Barriers towards proper follow-up and monitoring of outcome e.g. privacy legislation must be considered with a view to future patient mobility. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
33. Integrated prostate cancer centers might cause an overutilization of radiotherapy for low-risk prostate cancer: A comparison of treatment trends in the United States and Germany from 2004 to 2011.
- Author
-
Hager, Benjamin, Kraywinkel, Klaus, Keck, Bastian, Katalinic, Alexander, Meyer, Martin, Zeissig, Sylke Ruth, Stabenow, Roland, Froehner, Michael, and Huber, Johannes
- Subjects
- *
PROSTATE cancer treatment , *CANCER radiotherapy , *EPIDEMIOLOGY of cancer , *METASTASIS - Abstract
Introduction Aim of the study was to analyze changes in primary treatment for low-risk prostate cancer across different healthcare systems. Materials and methods We compared “Surveillance Epidemiology and End Results” data (USA) with data from four German federal epidemiological cancer registries, both from 2004 to 2011. We excluded metastatic disease and patients aged ⩾80 years. Thereof, we identified 132,506 (USA) and 54,159 (Germany) patients with low-risk according to the 2014 EAU guidelines. We tested treatment trends for statistical significance with a linear regression model. Results Active treatment was radical prostatectomy (RP) in 36.1% vs. 66.2% and radiotherapy (RT) in 38.4% vs. 11.8%. No active treatment (NAT) was reported in 24.2% vs. 16.2% ( p < 0.001 each). Through the study period the use of RP decreased from 37.1% to 34.2% in the USA ( p = 0.04) and was constant at a mean of 66.2% in Germany ( p = 0.8). The use of RT in the USA decreased from 42.8% to 31.8% ( p < 0.001), while it was stable in Germany ( p = 0.09). The NAT group grew from 18.0% to 33.2% in the USA ( p < 0.001), while it was stable in Germany until 2009 ( p = 0.3). From 2009 to 2011 there also was an increase of the NAT group in Germany from 15.2% to 19.4% ( p = 0.001). Conclusion In contrast to former evidence we found the relative use of RT for low-risk prostate cancer much higher in the USA compared to Germany. The implementation of integrated prostate cancer centers in the USA might explain this observation. Deferred and defensive treatment strategies showed a steady increase in the USA. This development seems delayed in Germany by several years. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
34. Non-Melanoma Skin Cancer Incidence and Impact of Skin Cancer Screening on Incidence.
- Author
-
Eisemann, Nora, Waldmann, Annika, Geller, Alan C, Weinstock, Martin A, Volkmer, Beate, Greinert, Ruediger, Breitbart, Eckhard W, and Katalinic, Alexander
- Subjects
- *
SKIN cancer , *MEDICAL screening , *AGE groups , *PUBLIC health , *CANCER research - Abstract
Non-melanoma skin cancer (NMSC) is the most common malignancy, whose public health significance is often unrecognized. This analysis has two objectives: first, to provide up-to-date incidence estimates by sex, age group, histological type, and body site; and second, to study the impact of skin cancer screening. The impact of screening on NMSC incidence in Schleswig-Holstein, Germany, is analyzed by comparing four time periods of different screening settings (no screening (1998-2000), pilot project (Skin Cancer Research to Provide Evidence for Effectiveness of Screening in Northern Germany, SCREEN, 2003-2004), after SCREEN (2004-2008), and nation-wide skin cancer screening (2008-2010)) to a reference region (Saarland, Germany). Age-standardized (Europe) NMSC incidence was 119/100,000 for women and 145/100,000 for men in the most recent screening period in Schleswig-Holstein (2008-2010). During implementation of SCREEN (2003-2004), incidence increased from 81.5/100,000 to 111.5/100,000 (1998-2000) by 47% for women and 34% for men. All age groups in women were affected by the increase, but increases for men were mostly limited to the older age groups. Incidence in Saarland first increased slowly, but increased steeply with the introduction of the nation-wide skin cancer screening in 2008 (+47% for women and +40% for men, reference 2004-2008). Observed changes are most likely attributed to screening activities. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
35. Population-based hormone receptor-specific incidence trends of breast cancer in Germany
- Author
-
Rusner, Carsten, Bandemer-Greulich, Ulrike, Engel, Jutta, Stegmaier, Christa, Zawinell, Anette, Holleczek, Bernd, Katalinic, Alexander, Kuss, Oliver, Schmidt-Pokrzywniak, Andrea, Schubert-Fritschle, Gabriele, Tillack, Anett, and Stang, Andreas
- Subjects
- *
BREAST cancer , *HORMONE receptors , *POSTMENOPAUSE , *CONFIDENCE intervals , *HORMONE therapy , *WOMEN'S health - Abstract
Abstract: Objectives: Several countries reported a drop in prescription of hormone replacement therapy (HRT) in the 2000s, followed by decreases in breast cancer incidence among postmenopausal women aged 50–69 years. The aim of this study was to provide hormone receptor specific incidence rates of breast cancer in Germany. Methods: Breast cancer data were extracted from the cancer registries of the Federal States of Brandenburg and Saarland and the area of Munich for the period from 1998 to 2007. We obtained nationwide data on HRT prescription in 1998–2007 from health insurances. Multiple imputation was used on missing values for the receptor status. Age-standardized (European standard population) and age-specific rates were calculated. Results: The age-standardized incidence rates in breast cancer were virtually constant over the entire period in all regions. In particular, no substantial changes over time occurred within the age- and receptor-specific analyses. In the same period we observed a drop in HRT use, starting in 1999 and leveling off in 2004. The incidence trends of carcinoma in situ of the female breast increased during the study period. Conclusions: In our data, we did not observe an association between the decline in HRT prescription and breast cancer incidence among women aged from 50 to 69 years. The lack of temporal changes in breast cancer incidence may be explained by introduction of opportunistic and organized mammography screening and low absolute levels of HRT prescription in Germany. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
36. Impact of the Quality assured Mamma Diagnostic (QuaMaDi) programme on survival of breast cancer patients
- Author
-
Obi, Nadia, Waldmann, Annika, Schäfer, Fritz, Schreer, Ingrid, and Katalinic, Alexander
- Subjects
- *
QUALITY assurance , *BREAST cancer diagnosis , *HEALTH surveys , *EPIDEMIOLOGY , *CANCER-related mortality , *MAMMOGRAMS , *MEDICAL screening - Abstract
Abstract: Objective: To evaluate the effect of the Quality assured Mamma Diagnostic programme (QuaMaDi) introduced in 2001 on breast cancer and mortality on a population basis. QuaMaDi provides a standardized diagnostic process for symptomatic or at risk women of all ages. The process includes independent double-reading of mammograms, additional ultrasound, and if suspicious an expert reading and assessment. We tested the hypothesis that QuaMaDi has influenced breast cancer epidemiology and survival positively. Methods: The QuaMaDi cohort of breast cancer patients, diagnosed within the programme between 2001 and 2007, was linked to the cancer registry dataset of all breast cancer cases in Schleswig-Holstein, Germany. By this record-linkage procedure participants of QuaMaDi could be marked in the cancer registry data. Overall survival rates of 3096 patients diagnosed within QuaMaDi were compared to 5417 patients diagnosed outside QuaMaDi, matched by year of diagnosis, using multivariate Cox proportional hazard models. Results: Crude hazard ratio for overall survival was HR 0.43 (95% CI 0.35–0.52) for breast cancer cases detected inside QuaMaDi versus those diagnosed outside the programme. After stepwise adjustment for age, grading, histology, treatment, and tumour stage, the survival advantage in QuaMaDi diagnosed breast cancer patients was still statistically significant (HR 0.78, 95% CI 0.64–0.96). Conclusion: Evidence is provided that the QuaMaDi programme has a beneficial impact on the first 5-year overall survival rate after breast cancer beyond a favourable tumour stage distribution. Thus, we conclude that QuaMaDi contributes to improved health care for women, who are not eligible for mammography screening. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
37. A nationwide population-based skin cancer screening in Germany: Proceedings of the first meeting of the International Task Force on Skin Cancer Screening and Prevention (September 24 and 25, 2009)
- Author
-
Geller, Alan C., Greinert, Rüdiger, Sinclair, Craig, Weinstock, Martin A., Aitken, Joanne, Boniol, Mathieu, Capellaro, Marcus, Doré, Jean-Francois, Elwood, Mark, Fletcher, Suzanne W., Gallagher, Richard, Gandini, Sara, Halpern, Allan C., Katalinic, Alexander, Lucas, Robin, Marghoob, Ashfag A., Nolte, Sandra, Schüz, Joachim, Tucker, Margaret A., and Volkmer, Beate
- Subjects
- *
SKIN cancer , *MEDICAL screening , *EARLY diagnosis , *DISEASE incidence , *CANCER prevention - Abstract
Abstract: Skin cancer incidence is increasing worldwide in white populations and mortality rates have not declined throughout most of the world. An extraordinarily high proportion of at-risk individuals have yet to be screened for melanoma but guidelines from esteemed bodies do not currently endorse population-based screening. Evidence for the effectiveness of skin cancer screening is imperative. To this end, scientists in Germany have launched a nationwide skin cancer screening campaign. Herein, we review pilot screening data from Schleswig-Holstein, discuss the launch of the major new national initiative, review issues related to evaluation of that program, and propose seven recommendations from the International Task Force on Skin Cancer Screening and Prevention that was held in Hamburg, Germany, on September 24 and 25, 2009. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.